Terry Ann Burrell Beam Therapeutics Inc. (BEAM) insider trading activity

Terry Ann Burrell is Chief Financial Officer of Beam Therapeutics Inc.. Currently has a direct ownership of 82,637 shares of BEAM, which is worth approximately $2.02 Million. The most recent transaction as insider was on Apr 26, 2024, when has been sold 12,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 82.6K

0% 3M change

75.39% 12M change

Total Value Held $2.02 Million

Terry-Ann Burrell Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 26 2024	BUY Grant, award, or other acquisition	-	12,500 Added 13.14%	82,637 Common Stock
Apr 01 2024	SELL Open market or private sale	$174,925 $32.12 p/Share	5,446 Reduced 7.21%	70,137 Common Stock
Mar 31 2024	BUY Grant, award, or other acquisition	-	27,500 Added 26.68%	75,583 Common Stock
Apr 04 2023	SELL Open market or private sale	$63,590 $29.09 p/Share	2,186 Reduced 4.43%	47,117 Common Stock
Apr 03 2023	SELL Open market or private sale	$74,380 $30.31 p/Share	2,454 Reduced 4.74%	49,303 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	-	20,000 Added 28.06%	51,277 Common Stock
Jan 27 2023	SELL Open market or private sale	$1,629,732 $45.08 p/Share	36,152 Reduced 53.61%	31,277 Common Stock
Jan 27 2023	BUY Exercise of conversion of derivative security	$494,559 $13.68 p/Share	36,152 Added 34.9%	67,429 Common Stock
Jan 26 2023	SELL Open market or private sale	$49,766 $45.16 p/Share	1,102 Reduced 3.4%	31,277 Common Stock
Jan 26 2023	BUY Exercise of conversion of derivative security	$15,075 $13.68 p/Share	1,102 Added 3.29%	32,379 Common Stock
Jan 24 2023	SELL Open market or private sale	$666,598 $45.01 p/Share	14,810 Reduced 32.13%	31,277 Common Stock
Jan 24 2023	BUY Exercise of conversion of derivative security	$202,600 $13.68 p/Share	14,810 Added 24.32%	46,087 Common Stock
Jan 23 2023	SELL Open market or private sale	$244,278 $45.02 p/Share	5,426 Reduced 14.78%	31,277 Common Stock
Jan 23 2023	BUY Exercise of conversion of derivative security	$74,227 $13.68 p/Share	5,426 Added 12.88%	36,703 Common Stock
Jan 18 2023	SELL Open market or private sale	$2,130,382 $45.14 p/Share	47,195 Reduced 60.14%	31,277 Common Stock
Jan 18 2023	BUY Exercise of conversion of derivative security	$545,640 $13.68 p/Share	39,886 Added 33.7%	78,472 Common Stock
Mar 31 2022	SELL Open market or private sale	$105,630 $59.11 p/Share	1,787 Reduced 4.46%	38,278 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	-	15,000 Added 27.24%	40,065 Common Stock
Jun 30 2021	SELL Open market or private sale	$3,660,000 $122.0 p/Share	30,000 Reduced 54.74%	24,809 Common Stock
Jun 30 2021	BUY Exercise of conversion of derivative security	$410,400 $13.68 p/Share	30,000 Added 35.37%	54,809 Common Stock
Jun 28 2021	SELL Open market or private sale	$4,789,350 $106.43 p/Share	45,000 Reduced 64.46%	24,809 Common Stock
Jun 28 2021	BUY Exercise of conversion of derivative security	$615,600 $13.68 p/Share	45,000 Added 39.2%	69,809 Common Stock
Mar 31 2021	BUY Grant, award, or other acquisition	-	17,500 Added 41.36%	24,809 Common Stock
Jan 04 2021	SELL Open market or private sale	$2,029,500 $81.18 p/Share	25,000 Reduced 77.38%	7,309 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$342,000 $13.68 p/Share	25,000 Added 43.62%	32,309 Common Stock

Also insider at

RXRX

RECURSION PHARMACEUTICALS, INC. Healthcare

Director